Loading stock data…
$19.16+0.10 (+0.50%)
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
Vor Biopharma Inc. in the Healthcare sector is trading at $19.16 with a market capitalization of $1.1B. Wall Street consensus targets $39.00 (8 analysts), implying a +103.6% move over the next 12 months. The stock is currently 43% below its 52-week high of $33.42, remaining 12.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.85M↓ | -$35.16M↑ | -$35.96M↓ | -$28.11M↑ | -$274.28M |
| Net Income | -$62.81M↑ | -$219.59M↓ | $1.72B↑ | -$812.68M↑ | -$1.57B |
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia...